ARTICLE | Clinical News
Tibotec Phase II HIV data
February 9, 2001 8:00 AM UTC
Tibotec (Mechelen, Belgium) said that in a double-blind, placebo-controlled Phase II study in 43 treatment-naive HIV patients, its TMC120 non-nucleoside reverse transcriptase inhibitor gave a mean 1.5...